James Samuel Shannon - 18 Mar 2026 Form 3 Insider Report for ProQR Therapeutics N.V. (PRQR)

Role
Director
Signature
/s/ Pieter Erik de Ridders, Attorney-in-Fact
Issuer symbol
PRQR
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 16:01:16 UTC
Previous filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon James Samuel Director PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, LEIDEN, NETHERLANDS /s/ Pieter Erik de Ridders, Attorney-in-Fact 18 Mar 2026 0001485417

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRQR Ordinary Shares 61,538 18 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 33,069 $4.89 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 32,164 $4.90 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 27,500 $3.30 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 14,918 $15.78 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 24,615 $9.91 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,239 $4.20 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,931 $8.01 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 22,608 $3.41 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,489 $1.98 Direct F3
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 22,128 $2.65 Direct F4
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 25,192 $2.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney